Print

Merck & Co., Inc. (MRK) Drug Shows Promise in Kid's Aging Disease Study  
9/27/2012 7:47:05 AM

The first experimental drug for the treatment of progeria has brought hope for the families and people affected by the accelerated aging disease. Progeria patients who used a farnesyl transferase inhibitors (FTI) called lonafarnib were able to improve their cardiovascular health and increase their weight gain, problems usually associated with the condition. The drug was initially slated by manufacture Merck to treat brain cancer, but was found ineffective against that disease. "This is a fantastic first step," says Leslie Gordon, medical director for the Progeria Research Foundation, a physician at Boston Children's Hospital and Brown University and the mother of a child with progeria, told NPR.
//-->